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Abstract
Objectives
Tumour microenvironment heterogeneity is believed to play a key role in cancer progres-
sion and therapy resistance. However, little is known about micro regional distribution of
hypoxia, glycolysis and proliferation in spontaneous solid tumours. The overall aim was
simultaneous investigation of micro regional heterogeneity of 64Cu-ATSM (hypoxia) and
18F-FDG (glycolysis) uptake and correlation to endogenous markers of hypoxia, glycolysis,
proliferation and angiogenesis to better therapeutically target aggressive tumour regions
and prognosticate outcome.
Methods
Exploiting the different half-lives of 64Cu-ATSM (13h) and 18F-FDG (2h) enabled simulta-
neous investigation of micro regional distribution of hypoxia and glycolysis in 145 tumour
pieces from four spontaneous canine soft tissue sarcomas. Pairwise measurements of
radioactivity and gene expression of endogenous markers of hypoxia (HIF-1α, CAIX), gly-
colysis (HK2, GLUT1 and GLUT3), proliferation (Ki-67) and angiogenesis (VEGFA and TF)
were performed. Dual tracer autoradiography was compared with Ki-67
immunohistochemistry.
Results
Micro regional heterogeneity in hypoxia and glycolysis within and between tumour sections
of each tumour piece was observed. The spatial distribution of 64Cu-ATSM and 18F-FDG
was rather similar within each tumour section as reflected in moderate positive significant
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correlations between the two tracers (ρ = 0.3920–0.7807; p = 0.0180 –<0.0001) based on
pixel-to-pixel comparisons of autoradiographies and gamma counting of tumour pieces.
64Cu-ATSM and 18F-FDG correlated positively with gene expression of GLUT1 and GLUT3,
but negatively with HIF-1α and CAIX. Significant positive correlations were seen between
Ki-67 gene expression and 64Cu-ATSM (ρ = 0.5578, p = 0.0004) and 18F-FDG (ρ = 0.4629–
0.7001, p = 0.0001–0.0151). Ki-67 gene expression more consistently correlated with 18F-
FDG than with 64Cu-ATSM.
Conclusions
Micro regional heterogeneity of hypoxia and glycolysis was documented in spontaneous
canine soft tissue sarcomas. 64Cu-ATSM and 18F-FDG uptakes and distributions showed
significant moderate correlations at the micro regional level indicating overlapping, yet dif-
ferent information from the tracers.18F-FDG better reflected cell proliferation as measured
by Ki-67 gene expression than 64Cu-ATSM.
Introduction
Phenotypic and cellular heterogeneity within malignant tumours has been recognized since the
early days of cancer biology [1–3]. All constituents of the malignant tumour contribute to its
heterogeneity. Even though cancers were initially seen as solely consisting of cancer cells, they
are now appreciated as complex structures comprising also stromal cells and non-cellular con-
stituents [4–6]. Thus complex mechanisms involving both the cancer cells, with their acquired
hallmarks [7, 8], and the tumour microenvironment appear important during carcinogenesis,
progression and metastasis [8–10] and simultaneously contribute to the cellular and pheno-
typic heterogeneity of malignant tumours [3, 11].
Key factors in the microenvironment of malignant tumours include hypoxia, glycolysis and
proliferation. Cancer cells cover their energy demands through aerobic glycolysis (Warburg
effect), which also supplies the necessary building blocks for the biomass formed during con-
tinuous cancer cell proliferation [12–14]. Rapidly growing cancer cells will experience diffu-
sion-limited hypoxia as soon as the intercapillary distance of 120–130 μm for oxygen delivery
is exceeded [15, 16]. Hypoxia, through activation of hypoxia inducible factors (HIF), especially
HIF-1α, regulates a myriad of genes leading to adaptive and genetic changes in the cancer cells
resulting in survival advantages [17]. The changes induced by hypoxia include induction of
angiogenesis, increased glycolytic activity and increased proliferation. As the newly formed
tumour vasculature is highly disorganized and dysfunctional, impaired blood flow and conse-
quently perfusion-limited hypoxia will result [15, 18]. Furthermore waste products from
increased glycolysis, such as lactate will acidify the tumour microenvironment necessitating
further adaptations [14]. Thus the complex interplay and the changes occurring in the tumour
microenvironment result in a vicious circle driving the cancer cells towards a more aggressive
and malignant phenotype showing treatment resistance [17, 19–24]. As hypoxia, increased gly-
colytic activity and proliferation have been associated with a poor prognosis in different
human cancers [25–31], it is of special interest to evaluate cancers and potentially target ther-
apy with respect to these microenvironmental phenotypes and their heterogeneity.
Insights into the molecular aspects of the tumour microenvironment can be accomplished
non-invasively via positron emission tomography (PET). 2-deoxy-2-[18F]fluoro-D-glucose
(18F-FDG) is routinely used to detect malignant tumours due to their high glycolytic activity.
Furthermore it has been proposed as a surrogate marker of tumour hypoxia [32] due to the
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close link between hypoxia and increased glycolytic activity. However, studies comparing
18F-FDG uptake with different hypoxia PET tracers have been inconsistent and have shown
regional and tumour type differences in distribution of hypoxia and glycolysis [33–36].
One promising hypoxia selective PET tracer is Cu-diacetyl-bis(N4-methylthiosemicarba-
zone) (Cu-ATSM) [37], which labelled with different copper radioisotopes, has been shown to
reflect hypoxia in human studies of cervical cancer [27, 38]. Only a few comparative PET stud-
ies of 64Cu-ATSM and 18F-FDG have been performed in canine and human cancer patients
showing from moderate or strong positive significant correlations [39] to no significant corre-
lations [40]. However, due to the detection method in PET, simultaneous investigation of two
tracers is not possible. Dual tracer PET studies are thus subject to a time difference between the
scans during which changes in the microenvironment may occur. Furthermore the spatial reso-
lution of PET is limited considering the microscopic distances under which changes in the
microenvironment may occur and thus the true micro regional heterogeneity may not be regis-
tered. Simultaneous dual tracer comparisons of 64Cu-ATSM and 18F-FDG at the micro
regional level using autoradiography have only been performed in preclinical rodent tumour
studies showing poor correlations [41–45]. Recently a study described a comparison between
the micro regional extent of hypoxia measured by the radioactivity of 18F-fluoroazomycin ara-
binoside (FAZA) with gene expression of endogenous markers of hypoxia in small tumour
fragments [46]. A technique for pairwise measurement of mRNA transcript levels and hypoxia
examined by radioactivity of FAZA in small tumour fragments was described in mice with
murine and xenografted human tumours. The study concluded that carbonic anhydrase IX
and glucose transporter 1 were strongly correlated to hypoxia meassured by FAZA [46].
However, little is still known about the in vivo micro regional heterogeneity of the tumour
microenvironment regarding hypoxia, glycolysis and proliferation in spontaneous solid
tumours, as it is difficult to obtain adequate and representative tumour samples from human
cancer patients. As stated earlier, knowledge about the micro regional heterogeneity of the
tumour microenvironment may be of importance for the prognosis of a cancer patient and fur-
thermore could pave the way for more targeted and individualized treatment approaches.
Therefore the aim was to simultaneously investigate the micro regional heterogeneity of hyp-
oxia and glycolysis in canine cancer patients with spontaneous soft tissue sarcomas, examining
the uptake and distribution of 64Cu-ATSM and 18F-FDG, their potential spatial overlap as well
as their correlation to endogenous markers of hypoxia (HIF-1α, carbonic anhydrase IX
(CAIX)), glycolysis (hexokinase 2 (HK2) and glucose transporters GLUT1 and GLUT3), prolif-
eration (Ki-67) and angiogenesis (vascular endothelial growth factor (VEGFA) and tissue fac-
tor (TF)). The canine cancer model allowed for these studies to be performed in “full-size”
compared to human patients. It was hypothesized that micro regional heterogeneity would be
observed; that 64Cu-ATSM and 18F-FDG would show varying degrees of overlap and correla-
tion; that 64Cu-ATSM would correlate positively with gene expression of endogenous markers
of hypoxia, glycolysis and angiogenesis due to the important function of HIF-1α in their regu-
lation; that 18F-FDG would correlate with gene expression of genes involved in glycolysis; and
lastly that 64Cu-ATSM and 18F-FDG also to some extent would reflect tumour proliferation.
Materials and Methods
Ethics statement
The study protocol was approved by the Animal Ethics and Administrative Committee at the
Department of Veterinary Clinical and Animal Sciences, Faculty of Health and Medical Sci-
ences, University of Copenhagen, Denmark. Owners provided written informed consent prior
to inclusion of their dog.
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Study population
Canine cancer patients with histologically confirmed soft tissue sarcoma admitted to the Univer-
sity Hospital for Companion Animals at the Department of Veterinary Clinical and Animal Sci-
ences, Faculty of Health andMedical Sciences, University of Copenhagen Denmark from 2011 to
2013 were eligible for inclusion, if curable intent surgery was not possible or the owner declined
advanced surgery. Treatment consisting of tumour debulking followed by radiotherapy was
offered through participation in the study. Four canine cancer patients were prospectively
enrolled in the study (Table 1). As the study focus was on micro regional heterogeneity within
each individual tumour, the number of tumour pieces from each individual tumour was of
greater interest than the number of patients included. The canine cancer patients and their own-
ers had to fulfil a number of presuppositions to be eligible to the research project (transportation
between research localities, owner agreement, individual animal cooperation), thus far from all
cancer patients with soft tissue sarcomas admitted to the University Hospital for Companion
Animals could be included. To eliminate potential variations in results attributable to inclusion
of several cancer types, only spontanous canine soft tissue sarcomas were eligible for inclusion.
Due to missing data and too high reference gene instabilities (see below) patient 1 was
included only in the final analysis of the correlation between 64Cu-ATSM and 18F-FDG uptake
based on gamma counting.
Experimental setup
The canine cancer patients had a full oncological workup including staging. Prior to planned
surgery, the patients were fasted for 12 hours and blood samples confirmed normal serum glu-
cose concentrations and readiness for anaesthesia. Approximately 3 hours prior to surgery
64Cu-ATSM (Hevesy Laboratory, DTU Campus Risø, Denmark) was injected intravenously as
a bolus. 64Cu-ATSM activity in the syringe was recorded and the decay corrected injected activ-
ity calculated. The mean received dose of 64Cu-ATSM activity was 8.2 MBq/kg (range 7.2–9.5
MBq/kg). Approximately 1 hour prior to surgery the patients received an intravenous bolus of
18F-FDG (Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Den-
mark) with a mean activity of 7.8 MBq/kg (range 7.3–8.0 MBq/kg). All patients were moni-
tored after tracer administration. By utilizing the different half-lives of these two tracers it was
possible to investigate the two molecular targets (hypoxia and glycolysis) simultaneously.
Patients were pre-medicated, anesthetized and monitored during surgery according to the
standards of the University Hospital for Companion Animals (pre-medication with Metha-
done 0.2–0.3 mg/kg IM/IV, Diazepam 0.3mg/kg IM/IV or Ketamine and Midazolam, and if
necessary Atropine 0.02mg/kg IM; anaesthesia induction with Propofol 4mg/kg IV and
Table 1. Patient and tumour characteristics for the four canine cancer patients included in the study.
Patient
no.
Tumour type Location Grade Size Age of dog at
surgery
1 Recurrent soft tissue sarcoma Lateral carpus 2 22mm x 14,8mm x
1cm
8 yr
2 Soft tissue sarcoma (most likely peripheral nerve sheath tumour or
a perivascular wall tumour)
Lateral cheek 1 5,26cm x 7,2cm 10.5 yr
3 Recurrent soft tissue sarcoma (features of perivascular wall tumour) Lateral thigh 1 3cm x 2cm 8 yr
4 Maxillary ﬁbrosarcoma Dorso-lateral
nose
1 Approximately 7cm x
7cm
6 yr
Yr years.
doi:10.1371/journal.pone.0141379.t001
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maintenance through Sevoflurane or Isoflurane gas anaesthesia). All patients received post-
operative analgesia, and three patients (no. 1, 3 and 4) received post-operative radiotherapy of
6.5–7 Gy once a week for 4 weeks.
As soon as a tumour was excised, it was cut into variable sized pieces for either a) autoradi-
ography (AR) and immunohistochemistry (IHC) (2–4 pieces per tumour) or b) gamma count-
ing and quantitative real-time polymerase chain reaction (qPCR) (30–45 pieces per tumour). A
total of 145 tumour pieces from the four soft tissue sarcomas were examined.
Dual tracer autoradiography and image analysis
Tumour pieces for AR and IHC (approximately 10x10x10 mm) were snap-frozen in liquid
nitrogen and transferred to dry ice. Tumour pieces were embedded with Jung Tissue freezing
Medium1 (Leica Microsystems A/S, Ballerup, Denmark), cut into 8μm tissue sections on a
cryostat (Leica CM1850, Leica Microsystems A/S, Ballerup, Denmark) and thaw mounted on
microscope slides (Thermo Scientific Menzel-Gläser Superfrost Ultra Plus1microscope slides,
Gerhard Menzel GmbH, Braunschweig, Germany). Ten to twenty cryostat sections 215 μm
apart were made for each tumour. Slides with tissue sections were exposed to a phosphor imag-
ing screen (MultiSensitive Storage Screen, PerkinElmer, Waltham, MA, USA) for approxi-
mately 2 hours. The exposed imaging screens were scanned at 600 dpi (pixel size 42 μm) using
a phosphor imaging system (Cyclone1 Plus, Storage Phosphor System, PerkinElmer, Wal-
tham, MA, USA) to obtain the first image (18F-FDG + 64Cu-ATSM). After approximately 12
hours for residual 18F-FDG to decay, slides were re-exposed to the phosphor imaging screen
for approximately 11 hours before the second reading. This was to ensure that the second scan
strictly expressed 64Cu-ATSM. All exposures were conducted at 4°C and slides subsequently
frozen and stored at -80°C until IHC analysis.
All AR images (pixel size 42 μm) were exported from OptiQuant™ Image Analysis Software
(PerkinElmer, Waltham, MA, USA) in TIFF format and transferred for further analysis using
in-house developed software in MATLAB (Version R2014a, The Mathworks, Inc., Natick, MA,
USA). The AR images of individual tumour tissue sections were cropped from a large image of
the whole phosphor imaging screen containing multiple sections. The two individual tumour
images (combined 18F-FDG + 64Cu-ATSM and pure 64Cu-ATSM exposure) were co-registered
using a rigid transformation and built-in functions, and their intensity corrected linearly for
exposure time and scan time difference. By subtracting the pure 64Cu-ATSM from the com-
bined image, an estimated pure 18F-FDG exposure was obtained. After quadruple down sam-
pling to reduce registration artefacts, direct pixel-to-pixel correlation of the two radioisotopes
was made and plotted in a scatter plot. Two Gaussian distributions were fitted to the data using
hierarchical cluster analysis, one for image background and one for the AR slide itself, and lin-
ear fits and coefficients of determination (R2) were calculated for each distribution.
Ki-67 immunohistochemistry and comparison with autoradiography
Four to eight cryostat sections (most often 430 μm apart) from each canine cancer patient pre-
viously used for AR were thawed, followed by fixation in acetone at 4◦C for 10 min. Manual
staining procedures were performed as follows: After air-drying, antigen retrieval with micro-
wave heating in citrate buffer, followed by a rinse in phosphate buffered saline (PBS) with 0.1%
Tween, was performed. Endogenous enzyme activity was blocked through 8 min soak with
Dako REALTM peroxidase-blocking solution (Dako, Glostrup, Denmark) and 10 min soak
with 2% bovine serum albumin (BSA). Incubation with monoclonal mouse anti-human anti-
body for Ki-67 antigen clone MIB-1 (Dako, Glostrup, Denmark) lasted 1 hour at room temper-
ature at a concentration of 1:200. This antibody also cross-reacts with canine Ki-67. The
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secondary antibody, an anti-mouse peroxidase labelled polymer (Envision+ System-HRP,
Dako, Glostrup, Denmark) was linked to the primary antibody during 40 min of incubation
and peroxidase activity was visualized through addition of DAB+ Subtrate Chromogen (Dako,
Glostrup, Denmark) as detection system. Counterstaining was performed with Mayer’s haema-
toxylin (Clinical Pharmaceutical Service, Copenhagen University Hospital Pharmacy, Den-
mark) before dehydration and mounting of cover glass. Each of the described steps until and
including DAB+ was followed by rinses with PBS, except between the BSA and primary anti-
body. An 8 μm cryostat section of canine epidermis was included in the run as a positive con-
trol of staining only in the basal layer. The rest of the epidermis simultaneously served as
negative control tissue. Furthermore a negative control, where the primary antibody was
replaced with nonsense anti-body (FLEX Negative Control Mouse, Dako, Glostrup, Denmark)
was also included.
IHC slides were scanned with Axio Scan.Z1slide scanner (Carl Zeiss Microscopy GmbH,
Jena, Germany) and images (pixel size 0.22 μm) processed in ZEN 2012 software (Carl Zeiss
Microscopy GmbH, Jena, Germany). Images resized to 25% (pixel size 0.88 μm) of the original
were exported from ZEN 2012 as PNG files for subsequent analysis of correlation between the
Ki-67 IHC and 64Cu-ATSM and 18F-FDG AR images. IHC images (one per tumour) were pro-
cessed and manually co-registered with AR images of 64Cu-ATSM and 18F-FDG using ImageJ
(public domain, Java-based image processing program) and MATLAB (version R2014b, The
Mathworks, Inc., Natick, MA, USA). Colour de-convolution of the IHC images focussing on
the brown colour indicating Ki-67 staining and the blue colour indicating nuclear staining was
performed. The original IHC image rescaled to a pixel size of 42 μm (size of AR) using pixel
averaging with bicubic interprolation was used for manual co-registration with AR images. A
mask drawn on the original IHC image to exclude areas of tissue folding or defects was after
rescaling overlaid on the AR images, rescaled brown IHC image and rescaled blue IHC image
before data extraction. Furthermore the rescaled brown IHC and blue IHC images were dichot-
omized to be either positive (1) or negative (0) for the respective stains before data extraction.
The corresponding values of Ki-67 immunostaining relative to blue nuclear staining (number
of positive brown pixels/number of positive blue pixels) and of tracer uptake (counts) were
evaluated for areas of 10 x 10 pixels (420 μm x 420 μm) at a time by taking the average. Pixels
lining the edges of the mask delineating the tissue of interest were excluded during this proce-
dure and an equal cell distribution within the examined tissue of interest was assumed. Hereby
correlations between Ki-67 IHC as a marker of proliferation and tracer uptake of 64Cu-ATSM
(hypoxia) or 18F-FDG (glycolysis) could be established.
Gamma counting and calculation of a standardized uptake value of
64Cu-ATSM and 18F-FDG for each tumour biopsy
The 30–45 tumour pieces (approximately 5 x 5 x 5 mm) from each tumour, to be evaluated by
gamma counting and qPCR, were individually placed in pre-weighed Eppendorf tubes contain-
ing RNAlater (Ambion Inc. Austin, TX, USA). Tubes were weighed and using a WIZARD21
Automatic gamma counter (model 2480, PerkinElmer, Waltham, MA, USA) gamma counting
of each tumour piece was performed twice approximately 19 hours apart. Thereby the first
gamma count would be a mixed count of 64Cu-ATSM and 18F-FDG, while the second count
represented solely 64Cu-ATSM. Empty Eppendorf tubes were counted to correct for the back-
ground count rate. The counting efficiency of the equipment was 9.43 x 10−2 for 64Cu-ATSM
and 0.54 for 18F-FDG.
Based on the gamma counting data, the matrix functions MMINVERSE and MMULT
(Microsoft1 Excel1 for mac 2011, version 14.3.8, Microsoft Corporation, Remond, WA, USA)
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were applied to solve the following two equations with two unknowns with regard to A064CuATSM
and A018FFDG
for each tumour piece to ﬁnd the activity of 64Cu-ATSM and 18F-FDG.
Rs1 ¼ RT1 RB1 ¼ ε18FFDG  A018FFDG þ ε64CuATSM  A064CuATSM
Rs2 ¼ ε18FFDG  A018FFDG  e
l18FFDG t2 þ ε64CuATSM  A064CuATSM  e
l64CuATSM t2
RS1, RT1 and RB1is the net count rate, total count rate and background count rate for the
ﬁrst gamma count, respectively, while RS2 is the net count rate for the second gamma count.
ε64CuATSM and ε18FFDG are the counting efﬁciencies for
64Cu-ATSM and 18F-FDG respectively,
while l64CuATSM and l18FFDG are their decay constants. t2 represents the time between the begin-
ning of the two gamma counts for a given tumour piece. Finally A064CuATSM
and A018FFDG
are the
activities of 64Cu-ATSM and 18F-FDG at the time of the ﬁrst gamma count for a given tumour
piece. These activities were converted to a standardized uptake value (SUV) by taking the
weight of the tumour piece, the canine patient’s body weight (BW) and the injected dose into
consideration [47, 48]:
SUV ¼ Activity in tumour piece ðkBq=mlÞ
Injected tracer activity ðMBqÞ=BW ðkgÞ
Quantitative real-time polymerase chain reaction
The gamma counted tumour pieces were stored in RNAlater for approximately 24 hours at
4°C before removing the supernatant and storing the tissue at -80°C until use.
Total RNA extraction and reverse transcription. RNAzol1RT (Molecular Research Cen-
ter Inc., Cincinnati, OH, USA), including the 4-bromoanisole (BAN) step to further eliminate
genomic DNA contamination, was used according to the manufacturer’s protocol to extract
total RNA from each tumour piece (13.4–510.9 mg). The tissue was lysed and homogenized in
Precellys1-24 (Bertin Technologies, Montigny, France).
The total RNA concentration was determined by NanoDrop 1000 (Thermo Fisher Scien-
tific, Waltham, MA, USA) to be between 262.4 and 4368.3 ng RNA/μL. To further minimize
genomic DNA contamination, all RNA samples were treated with rDNAse (Macherey-Nagel,
Düren, Germany) according to the manufactures’ protocol, except for the incubations which
were performed at 75°C for 15 minutes and at 4°C for 15 minutes. The quality of the isolated
RNA was measured as the RNA Integrity Number (RIN) on a 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA, USA). RIN values were between 5.4 and 9, verifying good RNA qual-
ity [49].
Total RNA (0.3 μg) was reverse transcribed (RT) using AffinityScriptTM QPCR cDNA syn-
thesis kit (cat.no. 600559, Stratagene, Santa Clara, CA, USA): Seven μL RNA (0.3 μg) + 2.45 μL
oligo (dT) primer (0.1 μg/μL) + 0.55 μL random primer (0.1 μg/μL) + 10 μL First Strand Master
Mix (2x) + 1 μL StrataScript RT-Rnaseblock; ending up with a final volume of 21 μL cDNA.
RT was performed on a MasterCycler Gradient (Eppendorf AG, Hamburg, Germany): incuba-
tion at 25°C for 5 minutes (primer annealing), 42°C for 15 minutes (cDNA synthesis) and
95°C for 5 minutes (termination of cDNA synthesis). Immediately after the cDNA was cooled
down, frozen and stored at -20°C.
Primers and TaqMan dual-labelled probes. Canine β-Glucuronidase (c_GUSB,
NM_001003191) and proteasome subunit, beta type, 6 (c_PSMB6, XM_844148) were selected
as reference genes, based on our previous study of suitable reference genes in similar tissues
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[50]. In brief this study demonstrated how to identify suitable reference genes for normaliza-
tion of genes of interest (GOIs) in canine soft tissues sarcomas using qPCR and report these
according to the MIQE guidelines [51]. Primer pairs for 17 potential reference genes were
designed and investigated in archival tumour biopsies from 6 canine soft tissue sarcomas by
quantifying the gene expression in duplicate samples run in SYBRGreen I. geNorm [52] imple-
mented in the qBasePLUS software [53] (Biogazelle NV, Zwijnaarde, Belgium) was used to iden-
tify the optimal number of reference genes and determine these.
In the present study GUSB and PSMB6 were designed in a TaqMan duplex assay while
GOIs were designed as multiplex (duplex or triplex) or simplex TaqMan assays. The following
GOIs were investigated: c_Ki-67 (XM_005637893) indicating proliferation; c_CAIX
(NM_001145174) and c_HIF-1α (XM_003639201) as measures of hypoxia; c_TF
(NM_001024640) and c_VEGFA (NM_0010003175) representing angiogenesis and c_HK2
(XM_003639587), c_GLUT1 (NM_001159326) and c_GLUT3 (NM_0010003308) as indica-
tors of glycolysis.
Beacon Designer (version 8.02–8.12, Premier BioSoft, Palo Alto, CA, USA) was used to
design primers and probes. Before designing, all genes were tested for cross homology against
the canine genome and checked for secondary structures. Since HIF-1α exists in 2 transcript
variants and VEGFA in 3, the amplicons for these two targets were placed in a way including
all transcript variants. The optimized conditions for the primers and probes, after testing and
securing one melting product and an efficiency of 100 ± 10%, are listed in Table 2. Primers and
probes were purchased from Sigma-Aldrich (St. Louis, MO, USA). Final qPCR designs are
listed in Table 3.
qPCR. Gene expression was quantified on the Mx3005P real-time PCR systems from Stra-
tagene (Santa Clara, CA, USA) using Brilliant III Ultra-Fast QPCRMaster Mix (Stratagene,
cat. no. 600880) for the simplex assays and Brilliant Multiplex QPCRMaster Mix (Stratagene,
cat. no. 600553) for the multiplex assays. The thermal profile for Brilliant III Ultra-Fast reagent
was: 3 minutes of denaturation at 95°C, followed by 40 cycles with denaturation at 95°C for 20
seconds and annealing/elongation at 60°C for 20 seconds. For the Brilliant Multiplex reagent,
the thermal profile was: denaturation at 95°C for 10 minutes, followed by 40 cycles with dena-
turation at 95°C for 15 seconds and annealing/elongation at 60°C for 1 minute.
Table 2. Optimized primer- and TaqMan probe concentrations for the genes investigated.
Gene Forward primer Final concentration
(nM)
Reverse primer Final concentration
(nM)
TaqMan probe Final concentration
(nM)
Reference genes
c_GUSB (GUSB) 300 600 300
c_PSMB6 (PSMB6) 300 300 250
Genes of interest (GOIs)
c_Ki-67 (MKI67) 300 600 300
c_CAIX (CA9) 600 600 200
c_HIF-1α (HIF1A) 600 300 250
c_TF (TF) 300 600 250
c_VEGFA (VEGFA) 600 300 300
c_GLUT1 (SLC2A1) 300 600 150
c_HK2
(LOC100856448)
300 300 250
c_GLUT3 (SLC2A3) 600 600 300
doi:10.1371/journal.pone.0141379.t002
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Samples were run in duplicates using 1 μL cDNA in a total volume of 20 and 25 μL, respec-
tively. A duplicate NO RT (no reverse transcription), indicating contamination with genomic
DNA in the sample, was included for each sample using a dilution of the respective sample
mRNA. Furthermore a NTC (no template control) and a dilution curve, used for efficiency cal-
culations, were included alongside three inter-run calibration samples in each run.
qPCR data analysis. qBasePLUS software based on the comparative 2-ΔΔCq method [54] for
relative quantification was used to analyse the qPCR data for each tumour individually. Sam-
ples with the following criteria were excluded from the analysis: a) a difference in Cq value
between the sample and the corresponding NO RT of less than 5 Cq, b) a replicate variability
difference in Cq value of more than 0.5 Cq. Normalization to two reference genes was included
based on the findings in our previous study [50]. The software also calculated the stability of
the two selected reference genes. We only accepted a reference target stability value M below
1.44 and a CV-value below 0.58 due to the expected heterogeneous composition of the tumour
biopsies including both stromal, endothelial and tumour cells. Hereby we excluded patient 1
from further qPCR analysis. Furthermore the qBasePLUS software accounted for the three
inter-run calibrators for correction between PCR runs within the same gene. The data were
reported as calibrated normalized relative quantities (CNRQs).
Statistical analysis
Tumour piece uptake of 64Cu-ATSM and 18F-FDG calculated as SUV from gamma counts
were correlated to each other and the gene expression of GOIs using Spearmann’s rank correla-
tion in Graph Pad Prism (version 6.0e, GraphPad Software, Inc., La Jolla, CA, USA). MATLAB
(version R2014a, The Mathworks, Inc., Natick, MA, USA) was used for correlating 64Cu-
ATSM and 18F-FDG AR images to each other. Processing of data from IHC images and AR
images was done using Excel1 (Microsoft1 Excel1 for mac 2011, version 14.3.8, Microsoft
Corporation, Redmond, WA, USA) and Graph Pad Prism (version 6.0e, GraphPad Software,
Inc., La Jolla, CA, USA) to calculate Spermann’s rank correlations between Ki-67 immunos-
taining and 64Cu-ATSM and 18F-FDG in tumour tissue sections. For all statistical analyses a p-
value< 0.05 was considered significant.
Results
Micro regional uptake, distribution and correlation of 64Cu-ATSM and
18F-FDG
As exemplified in Fig 1 varying degrees of micro regional tumour heterogeneity in hypoxia, as
per 64Cu-ATSM uptake, and glycolysis, as per 18F-FDG uptake, within tumour tissue sections
from each tumour was observed. Visual examination of AR images of 64Cu-ATSM and 18F-FDG
likewise revealed different degrees of micro regional heterogeneity in the uptake of the two tracers
between distinct tumour tissue sections from each individual tumour as well as between the four
examined sarcomas. However the spatial distribution of 64Cu-ATSM and 18F-FDG was rather
similar within each tumour tissue section, which was also reflected in the positive correlations
found in all AR images between the spatial distribution of 64Cu-ATSM and 18F-FDG based on
pixel-to-pixel analysis (Fig 2). Similarly, when correlating the SUVs of 64Cu-ATSM and 18F-FDG
for the multiple tumour pieces within each individual tumour, a moderate positive significant
correlation (ρ between 0.3920 and 0.7807; p between 0.0180 and<0.0001) between the two trac-
ers was seen in all four sarcomas (Fig 3).
Overall SUVs for each of the 30–45 pieces from the individual tumours calculated from the
gamma counts were generally lower for 64Cu-ATSM than for 18F-FDG for all four tumours
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(Table 4). Furthermore 64Cu-ATSM SUVs showed less variation between the individual
tumours compared to 18F-FDG SUVs (Table 4).
Ki-67 Immunohistochemistry: relation to 64Cu-ATSM and 18F-FDG
autoradiography
The proliferative state of the tumours, investigated through Ki-67 IHC, revealed an overall
scarce Ki-67 staining with a rather homogenous distribution without any obvious hotspots
within the tumour sections. When compared with the uptake of 64Cu-ATSM and 18F-FDG of
the corresponding AR images only for tumour 3 a significant but negative correlation was
found between Ki-67 IHC and 64Cu-ATSM (ρ = -0.5901; p = 0.0006). The remainder of the
correlations were non-significant (p between 0.2123 and 0.3663) or irrelevant (ρ between
-0.1433 and -0.1949). A visual example of the comparison between a Ki-67 IHC image and
18F-FDG and 64Cu-ATSM AR images is given in Fig 4.
Genes of interest: Relation to 64Cu-ATSM and 18F-FDG uptakes
In contrast to the Ki-67 IHC results, the pairwise measurements of relative gene expression
and radioactivity for the multiple tumour biopsies within each individual tumour revealed sig-
nificant positive correlations between Ki-67 gene expression and the uptake of 18F-FDG in all
Fig 1. Micro regional heterogeneity in distribution of 64Cu-ATSM (hypoxia) and 18F-FDG (glycolysis). Example of calculated 18F-FDG image (left) and
calculated 64Cu-ATSM image (right) from autoradiography of a tumour tissue section from tumour 4. Intensity levels in each image are individually optimized.
doi:10.1371/journal.pone.0141379.g001
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three tumours (Fig 5, right column), while this was only the case for one tumour (no. 3) when
correlating to the uptake of 64Cu-ATSM (Fig 5, left column).
Results from this tumour, regarding correlations of tracer uptake to hypoxic and glycolytic
gene expression markers, also demonstrated significance for both 64Cu-ATSM and 18F-FDG
(Fig 6). The gene expression of HIF-1α exhibited a significant negative correlation to both
18F-FDG (ρ = -0.5135; p = 0.0012) and 64Cu-ATSM (ρ = -0.5021; p = 0.0015), while the correla-
tions between the tracers and CAIX gene expression were non-significant. With regard to the
expression of GLUT1 and GLUT3 both 64Cu-ATSM and 18F-FDG showed positive correla-
tions, though not significant for GLUT1 versus 18F-FDG (ρ = 0.2537; p = 0.1414) (Fig 6). For
the angiogenic gene expression markers the correlations to tracer uptake were non-significant
for tumour 3, except for a positive significant correlation between 18F-FDG and TF (ρ = 0.4885;
p = 0.0046). Similarly, non-significant correlations were seen in the two other tumours (no. 2
and 4) for some of the investigated GOIs and no general trend was found within the significant
correlations (S1 Fig).
To further elucidate the significant correlations between the tracers and gene expressions
found in tumour 3, we correlated the gene expression of different GOIs to each other (Fig 7).
Fig 2. Correlation between 64Cu-ATSM and 18F-FDG distribution in autoradiography sections. Examples of calculated 18F-FDG images (first column)
and calculated 64Cu-ATSM images (second column) from the autoradiographies from tumour 2 (A), tumour 3 (B) and tumour 4 (C). The third column shows
the pixel-to-pixel plot, separating background (blue marks) and autoradiography (AR) image data (red marks) using cluster analysis. Images were
downscaled a factor of 4 for this analysis. The correlation of the non-background AR image is shown in the fourth column.
doi:10.1371/journal.pone.0141379.g002
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Discussion
This unique dual tracer study exploited the different half-lives of 64Cu and 18F to simulta-
neously investigate the micro regional heterogeneity of tumour microenvironment hypoxia
and glycolysis in canine soft tissue sarcomas using the PET tracers 64Cu-ATSM and 18F-FDG
Fig 3. Correlation between 64Cu-ATSM and 18F-FDG uptake in gamma counted tumour pieces. Spearman’s Rank correlations (ρ) and p-values for
comparison of intra-tumoural spatial distribution of 64Cu-ATSM and 18 F-FDG calculated as standardized uptake value (SUV) from gamma counts of tumour
pieces. a, b, c and d show data for tumour pieces from canine cancer patient 1, 2, 3 and 4, respectively. n is the number of tumour pieces included in the final
analysis. Significant correlations are written in bold.
doi:10.1371/journal.pone.0141379.g003
Table 4. Maximum andminimum standardized uptake values (SUV) for 64Cu-ATSM and 18F-FDG in
each tumour calculated fromwell counts on all biopsies.
18F-FDG SUV 64Cu-ATSM SUV
Tumour no. Minimum Maximum Minimum Maximum
1 0.79 1.52 0.42 0.68
2 0.53 1.77 0.49 0.96
3 0.08 2.81 0.10 1.80
4 1.40 3.93 0.66 1.80
doi:10.1371/journal.pone.0141379.t004
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and their relation to endogenous markers of hypoxia, glycolysis, proliferation and angiogenesis.
Importantly, it was for the first time in spontaneous canine soft tissue sarcomas simultaneously
demonstrated, that the uptake and spatial distribution of each of the tracers 64Cu-ATSM and
18F-FDG showed micro regional distribution differences, while the two tracers showed varying
degrees of overlapping micro regional distributions of hypoxia and glycolysis manifested in sig-
nificant moderate correlations between 64Cu-ATSM and 18F-FDG examined both through
gamma counting and autoradiographies. This demonstrates both some overlap but also
uniqueness of each of the PET tracers. The expression of the endogenous markers of hypoxia
and glycolysis showed similar significant correlations to both 64Cu-ATSM and 18F-FDG in one
tumour, while no particular trend was observed in the other tumours or for the endogenous
markers of angiogenesis potentially indicating differing molecular expression patterns in the
examined soft tissue sarcomas. With regard to tumour cell proliferation, gene expression of Ki-
67 and tracer uptake for 18F-FDG correlated closer than Ki-67 and 64Cu-ATSM, indicating
that 18F-FDG may be a better marker of proliferation.
Micro regional uptake, distribution and correlation of 64Cu-ATSM and
18F-FDG
As stated above the present study contributes with novel information about tumour heteroge-
neity of hypoxia, as per 64Cu-ATSM uptake, and glycolysis, as per 18F-FDG uptake, at the
micro regional level. It is innovative in simultaneously investigating two PET tracers in a spon-
taneous syngeneic translational animal cancer model and performing pairwise comparisons of
tracer uptake with endogenous markers in small tumour pieces. As hypothesized a moderate
significant correlation was found between the uptake and spatial distribution of 64Cu-ATSM
and 18F-FDG.
Other studies have also investigated the spatial overlap of 64Cu-ATSM and 18F-FDG using
either AR or PET image comparisons. Comparable to the results of the present study, a previous
canine study including both sarcomas and carcinomas reported moderate to strong spatial correla-
tions between 64Cu-ATSM (3 and 24 hours post injection) and 18F-FDG based on voxel compari-
sons of PET images, though without specifying the correlations according to histopathology or
uptake in multiple tumour pieces as in the present study [39]. In a similar cohort comparing 64Cu-
ATSM and 18F-FDG PET scan uptakes with immunohistochemical staining for the exogenous
hypoxia marker pimonidazole, it was found that tumours with high levels of pimonidazole staining
showed high uptake of 64Cu-ATSM (3 hours post injection) and 18F-FDG [39]. Furthermore
Fig 4. Ki-67 IHC versus 64Cu-ATSM and 18F-FDG autoradiography. Visual example of the comparison between a Ki-67 IHC image and 64Cu-ATSM and
18F-FDG autoradiography images for tumour 2. First column: Ki-67 IHC image rescaled to the same pixel size (42 μm) as the autoradiographies (AR). A
selection is chosen for illustration of correlations between Ki-67 IHC and 18F-FDG and 64Cu-ATSM AR respectively (columns 2–4).
doi:10.1371/journal.pone.0141379.g004
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comparison of 64Cu-ATSMAR (25 hours post injection) and pimonidazole IHC revealed similar
regional distributions in the most heterogeneous tumour regions. 18F-FDGAR however was not
available for comparison with pimonidazole and the study concluded that 18F-FDGmight not be a
surrogate marker of hypoxia [55]. In partial contrast the findings of moderate spatial micro
regional overlap between 64Cu-ATSM and 18F-FDG in the present study, a recent study in human
patients with head and neck cancer showed no significant difference in the biological tumour vol-
ume delineated for radiotherapy planning based on 64Cu-ATSM PET/CT or 18F-FDG PET. How-
ever the correlation analysis was not described in detail [40]. A newer PET study of canine
sinonasal cancers did not find as strong spatial correlations between 61Cu-ATSM and 18F-FDG for
sarcomas as it did for carcinomas [56], suggesting that tumour type differences may exist. The
present study cannot evaluate this, as only canine soft tissue sarcomas were examined. However
earlier rodent model studies also revealed differences in 64Cu-ATSM uptake between various can-
cers [57].
In contrast to the results of the present study, poor correlations between the micro regional
distribution of 64Cu-ATSM and 18F-FDG evaluated by AR have been seen in preclinical studies
in both mouse [41, 42], rat [43, 44] and rabbit tumour models [45]. A very recent study using
64Cu-ATSM and 18F-FDG PET/CT scans in canine spontaneous carcinomas and sarcomas for
dose painting also revealed varying degrees of correlation between dose plans based on the two
tracers [58]. Furthermore it was found that 18F-FDG based dose painting plans only covered
Fig 5. Correlation between gene expression of Ki-67 and 64Cu-ATSM and 18F-FDG uptake. Spearman’s Rank correlations (ρ) and p-values for
comparison of gene expression for Ki-67 and tumour uptake of 18F-FDG (right column) and 64Cu-ATSM (left column) calculated as standardized uptake
value (SUV) from gamma counts of tumour pieces. Row A, B andC show data for tumour pieces from canine cancer patient 2, 3 and 4 respectively. n is the
number of tumour pieces included in the final analysis. n.s. not significant. Significant correlations are written in bold.
doi:10.1371/journal.pone.0141379.g005
Fig 6. Correlations between hypoxic and glycolytic gene expressions and 64Cu-ATSM and 18F-FDG uptake, tumour 3. Spearman’s Rank correlations
(ρ) and p-values for comparison of gene expressions for GLUT1, GLUT3, HIF-1α and CAIX respectively and tumour uptake of 18 F-FDG (upper row) and
64Cu-ATSM (lower row) calculated as standardized uptake value (SUV) from gamma counts. n is the number of tumour pieces included in the final analysis.
n.s. not significant. Significant correlations are written in bold.
doi:10.1371/journal.pone.0141379.g006
Heterogeneity in ⁶⁴Cu-ATSM and ¹⁸F-FDG Uptake in Canine Sarcomas
PLOSONE | DOI:10.1371/journal.pone.0141379 October 26, 2015 16 / 25
Heterogeneity in ⁶⁴Cu-ATSM and ¹⁸F-FDG Uptake in Canine Sarcomas
PLOSONE | DOI:10.1371/journal.pone.0141379 October 26, 2015 17 / 25
approximately 50% of the hypoxic regions adequately, leading to the conclusion that 64Cu-
ATSM and 18F-FDG provide different biological information [58]. In agreement with this, the
present study showed only a moderate overlap between 64Cu-ATSM and 18F-FDG in canine
soft tissue sarcomas, but with the novelty of being evaluated simultaneously and at the micro
regional level. In addition, the present study revealed varying degrees of heterogeneous distri-
bution of each individual tracer within and between tumour tissue sections from each tumour,
indicating the existence of tumour heterogeneity in hypoxia and glycolysis at the micro
regional level. In sum, in some circumstances 64Cu-ATSM and 18F-FDG may be closely related
but this is not always the case. Therefore, both tracers have their value when phenotyping
tumours and 64Cu-ATSM is justified as an adjunct to 18F-FDG imaging.
Gene expression of endogenous markers of hypoxia, glycolysis and
angiogenesis in relation to 64Cu-ATSM and 18F-FDG uptakes calculated
from gamma counts
The multiple pairwise measurements of radioactivity attributable to 64Cu-ATSM and 18F-FDG
respectively and the gene expressions of endogenous markers in small tumour pieces helped
elucidate the true connections between tracer uptake and molecular events on a micro regional
level and gave insights into micro regional heterogeneity. Significant correlations between the
gene expression of endogenous markers of hypoxia and glycolysis and the PET tracer uptakes
were seen with similar correlations for both 64Cu-ATSM and 18F-FDG in one tumour (no. 3),
while no particular trend was seen for the endogenous markers of angiogenesis or in the other
tumours, indicating potential differences in molecular expressions in the investigated tumours.
The correlations between tracer uptake and gene expression in tumour 3 revealed a positive
correlation between 18F-FDG and the mRNA encoding the glucose transporters GLUT1 and
GLUT3 as expected, though only significant for GLUT3. GLUT1 and GLUT3 are the primary
transporters facilitating uptake of glucose and thus also the glucose analogue 18F-FDG into the
tumour cells [59–61]. That 18F-FDG uptake only correlated significantly with GLUT3 may be
explained by the higher affinity for glucose and the greater transport capacity of this glucose
transporter compared to GLUT1 [62]. However it may also indicate that this transporter has
the main responsibility for glucose transport into cells in canine soft tissue sarcomas or be due
to post transcriptional or translational changes. The significant positive correlation seen
between 64Cu-ATSM and GLUT1 and especially GLUT3 reflects the close link between hyp-
oxia and increased glycolysis in tumours. Both GLUT1 and GLUT3 are known to be up-regu-
lated by HIF-1α during hypoxia [63, 64]. Interestingly enough we did not find a positive but
rather a negative correlation when comparing the gene expression of GLUT3 and, though not
significant, GLUT1 with HIF-1α gene expression in tumour 3. This discrepancy may be
explained by post transcriptional or translational modifications in HIF-1α, remembering that
the HIF-1α protein is the active transcription factor for hypoxia inducible genes [65, 66].
Another explanation for the negative correlations between HIF-1α and its target genes could
be the existence of acute or recent hypoxia within the cells leading to up-regulation of HIF-1α
while the transcription of the hypoxia responsive genes has not yet been significantly up
regulated.
Fig 7. Correlations between the gene expressions of different genes of interest, tumour 3. Spearman’s
Rank correlations (ρ) and p-values for all possible gen-gen correlations between GLUT1, GLUT3, HIF-1α,
CAIX and Ki-67. n is the number of tumour pieces included in the final analysis. n.s. not significant. Significant
correlations are written in bold.
doi:10.1371/journal.pone.0141379.g007
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We also found negative correlations between both 64Cu-ATSM and 18F-FDG with regard to
the gene expression of CAIX (though non-significant) and HIF-1α in tumour 3. For 18F-FDG
this seems reasonable, since this tracer is primarily a marker of tumour glycolysis. However
since the correlations were equal for 64Cu-ATSM and 18F-FDG a similar explanation for the
negative correlation for the two PET tracers may also be possible. One reason could be the
above-described delay in transcription of hypoxia responsive genes in areas of acute hypoxia.
Another explanation could be that HIF-1α is regulated by other factors than tumour hypoxia,
such as oncogenic signalling or growth factors [67–69]. Probably this also explains why a lack
of correlation between hypoxia measurements and expression of HIF-1α and its target genes
have been seen not only in some of the tumours in the present study, but also in other studies
[70, 71]. Similarly, negative or non-significant correlations between CAIX and hypoxia mea-
surements have also been found in other studies [72].
Different explanations can be put forward to justify that tumour 3 showed significant corre-
lations between tracer uptake and gene expression with a noticeable trend for both tracers,
while more non-significant correlations and no specific trends were seen for the correlations in
the other sarcomas. The most plausible reason is the wider range of SUVs for both 64Cu-ATSM
and 18F-FDG in the tumour pieces from tumour 3 (Table 4). For the other tumours the range
in SUVs might be too narrow to find a significant correlation. Furthermore the fact that no sig-
nificant correlations or trends were seen for the correlations between 64Cu-ATSM and
18F-FDG and the gene expression of the endogenous markers of angiogenesis in tumour 3 may
not necessarily be interpreted as a negative result, but rather as an indication that different and
further information about the micro regional molecular aspects are gained through simulta-
neous investigations using several molecular techniques. The gene expression analysis of
endogenous markers in the present study thus indicated different molecular expressions in the
examined tumours despite their same histopathology. A very recent extensive study of molecu-
lar genetic patterns in 12 different human cancer types similarly revealed the existence of sub-
types within specific cancer types and additionally gathering of different histopathologic
tumour types into the same molecular subtype [73]. This indicates, that in the future malignant
tumours should not only be classified according to the traditional histopathologic classifica-
tion, but also or rather according to a molecular classification. Such a classification may be
facilitated by use of molecular imaging techniques as well as endogenous markers.
Correlations between endogenous markers of proliferation and 64Cu-
ATSM and 18F-FDG
With regard to proliferation as evidenced by Ki-67 protein and gene expression, a discrepancy
was seen between the correlations to the two tracers 64Cu-ATSM and 18F-FDG when using
gene expression and IHC, respectively. The results of the gene expression analysis of Ki-67
showed more positive significant correlations for 18F-FDG than for 64Cu-ATSM (Fig 5), indi-
cating that 18F-FDG may be a better marker of proliferation. With Ki-67 IHC no significant
correlations to either 64Cu-ATSM or 18F-FDG could be registered. Possible explanations for
this difference in results may be: 1) that tumour pieces used for gene expression analysis and
IHC originated from different areas of the tumour; 2) that post transcriptional or translational
changes happen between the mRNA measured during qPCR and the protein measured during
IHC; 3) that Ki-67 IHC staining was too scarce and homogenous; 4) the limitations associated
with comparing Ki-67 IHC and AR images having very different image resolutions. However
we tried to avoid small regional discrepancies in uptake and possible manual co-registration
inaccuracies by investigating areas of 420 x 420 μm without compromising the interest of get-
ting micro regional information.
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Studies in different human cancers have also revealed significant correlations between Ki-67
and 18F-FDG e.g. in lymphomas [74], non-small-cell lung cancer [75, 76] and bone and soft tis-
sue sarcomas [77]. However a preliminary study of human malignant melanomas revealed no
significant link between 18F-FDG uptake and Ki-67 grades [78]. All these studies compared
18F-FDG uptake from PET scans with Ki-67 immunostaining in contrast to the present study
where the micro regional tracer uptake is correlated to gene expression of Ki-67. However a
very recent study in human colon cancer showed a positive correlation between maximum
18F-FDG uptake from PET scans and the gene-expression of Ki-67 [79]. Studies comparing
64Cu-ATSM and Ki-67 are scarcer and only preclinical comparing immunohistochemistry and
autoradiographies [41, 42]. Therefore the significant correlations seen between 18F-FDG and
Ki-67 gene expression in the present study represent special information about the micro
regional relationship between glycolysis and proliferation in solid tumours, which is in agree-
ment with our hypothesis.
Conclusion
In conclusion this study of canine soft tissue sarcomas revealed that both 64Cu-ATSM and
18F-FDG uptake is heterogenous across multiple micro regions within and between tumours of
the same histopathologic class. At the micro regional level 64Cu-ATSM and 18F-FDG uptakes
and distributions only correlated moderately indicating different biological aspects visualized.
18F-FDG better reflected cell proliferation as measured by Ki-67 gene expression than did
64Cu-ATSM. Thus each PET tracer contributes with distinct information about the micro
regional environment within the cancer. Using endogenous molecular markers also adds rele-
vant information about the microenvironment and heterogeneity and perhaps a molecular tax-
onomy of cancers may in the future become as important as that of traditional histopathologic
classification of cancers. Since the number and types of tumours in the present study were lim-
ited, further studies are necessary to investigate whether the observations in the present study
are generalizable.
Supporting Information
S1 Fig. Correlations between glycolytic, hypoxic and angiogenic gene expressions and
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